Patient Priorities Concerning Treatment Decisions for Advanced Neuroendocrine Tumors Identified by Discrete Choice Experiments
The Oncologist · 2024
DOI: 10.1093/oncolo/oyad312 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2024. Verfasst von Matthew Anaka und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cross Cancer Institute, Alberta Health Services, Edmonton, Alberta, Canada. Hauptthemen laut MEDLINE: Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Commonwealth Neuroendocrine Tumour research collaborative.
Abstract (Originalsprache)
Background
Patients with advanced neuroendocrine tumors (NETs) have multiple treatment options. Ideally, treatment decisions are shared between physician and patient; however, previous studies suggest that oncologists and patients place different value on treatment attributes such as adverse event (AE) rates. High-quality information on NET patient treatment preferences may facilitate patient-centered decision making by helping clinicians understand patient priorities.
Methods
This study used 2 discrete choice experiments (DCE) to elicit preferences of NET patients regarding advanced midgut and pancreatic NET (pNET) treatments. The DCEs used the “potentially all pairwise rankings of all possible alternatives” (PAPRIKA) method. The primary objective was to determine relative utility rankings for treatment attributes, including progression-free survival (PFS), treatment modality, and AE rates. Ranking of attribute profiles matching specific treatments was also determined. Levels for treatment attributes were obtained from randomized clinical trial data of NET treatments.
Results
One hundred and 10 participants completed the midgut NET DCE, and 132 completed the pNET DCE. Longer PFS was the highest ranked treatment attribute in 64.5% of participants in the midgut NET DCE, and in 59% in the pNET DCE. Approximately, 40% of participants in both scenarios prioritized lower AE rates or less invasive treatment modalities over PFS. Ranking of treatment profiles in the midgut NET scenario identified 60.9% of participants favoring peptide receptor radionuclide therapy (PRRT), and 30.0% somatostatin analogue dose escalation.
Conclusion
NET patients have heterogeneous priorities when choosing between treatment options based on the results of 2 independent DCEs. These results highlight the importance of shared decision making for NET patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cross Cancer Institute, Alberta Health Services, Edmonton, Alberta, Canada.
- Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
- Northern Sydney Cancer Centre, St Leonards, New South Wales, Australia.
- Department of Medicine, Otago Medical School, University of Otago, Dunedin, Otago, New Zealand.
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
- Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
ORCID-Profile: Matthew Anaka, Eva Segelov
Förderung
- Commonwealth Neuroendocrine Tumour research collaborative
Zitieren
APA
Anaka, M., Chan, D., Pattison, S., Thawer, A., Franco, B., Moody, L., Jackson, C., Segelov, E., & Singh, S. (2024). Patient Priorities Concerning Treatment Decisions for Advanced Neuroendocrine Tumors Identified by Discrete Choice Experiments. The Oncologist. https://doi.org/10.1093/oncolo/oyad312
Vancouver
Anaka M, Chan D, Pattison S, Thawer A, Franco B, Moody L, et al. Patient Priorities Concerning Treatment Decisions for Advanced Neuroendocrine Tumors Identified by Discrete Choice Experiments. The Oncologist. 2024. doi:10.1093/oncolo/oyad312
BibTeX
@article{Anaka2024,
author = {Anaka, Matthew and Chan, David and Pattison, Sharon and Thawer, Alia and Franco, Bryan and Moody, Lesley and Jackson, Christopher and Segelov, Eva and Singh, Simron},
title = {Patient Priorities Concerning Treatment Decisions for Advanced Neuroendocrine Tumors Identified by Discrete Choice Experiments},
journal = {The Oncologist},
year = {2024},
doi = {10.1093/oncolo/oyad312}
}
EUVIMED